Search Results 501-510 of 18017 for Alopecia

1. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

   * Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.

2. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

3. Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial - Mayo Clinic

   following exceptions, which are allowed: alopecia, vitiligo, rheumatoid arthritis, psoriasis/psoriatic arthritis, Hashimoto's thyroiditis, lupus ...

4. Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors - Mayo Clinic

   ... alopecia prior to C1D1; Age eighteen years or older; ECOG performance status 0-2, inclusive; Anticipated life expectancy of at least 12 weeks; Adequate bone ...

5. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation - Mayo Clinic

   (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor.) ...

6. Long-term Safety and Effectiveness Study for Participants with Advanced Tumors who are Currently on Treatment or in Follow-up in a Pembrolizumab Trial - Mayo Clinic

   alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of >30 Gray (Gy), they must ...

7. Tucatinib and Trastuzumab for Patients with HER2-positive Metastatic Colorectal Cancer - Mayo Clinic

   Alopecia and neuropathy, which must have resolved to ≤ Grade 2;; Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of ...

8. Behcet disease - Symptoms and causes - Mayo Clinic

   Behcet (beh-CHET) disease, also called Behcet syndrome, is a rare condition. It causes blood vessel swelling, called inflammation, throughout the body. Behcet ...

9. Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer - Mayo Clinic

   All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1; Patients who are ...

10. Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer - Mayo Clinic

    Patients with vitiligo or alopecia; Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring ...